Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.

Blood - 11 Jan 2018

Bartlett Nancy L, Costello Brian A, LaPlant Betsy R, Ansell Stephen M, Kuruvilla John G, Reeder Craig B, Thye Lim S, Anderson Daniel M, Krysiak Kilannin, Ramirez Cody, Qi Jing, Siegel Barry A, Griffith Malachi, Griffith Obi L, Gomez Felicia, Fehniger Todd A

Abstract excerpt

Most patients with follicular lymphoma (FL) experience multiple relapses necessitating subsequent lines of therapy. Ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor approved for the treatment of several B-cell malignancies, showed promising activity in FL in a phase 1 study. We report the results of a phase 2 trial evaluating ibrutinib in recurrent FL. Forty patients with recurrent FL were treated with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Agammaglobulinaemia Tyrosine Kinase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CARD Signaling Adaptor Proteins

Share to Guanylate Cyclase

Share to Lymphoma, Follicular

Share to Piperidines

Share to Pyrazoles

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 29074501
DOI: 10.1182/blood-2017-09-804641
PMCID: PMC5757691

Genes

BTK
CARD11

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.PMID 29074501Read ↗

Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial.Semantic proximity Read ↗

Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in early-stage follicular lymphoma: TROG99.03Semantic proximity Read ↗

Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303.Semantic proximity Read ↗

Decreased Expression of T-Cell-Associated Immune Markers Predicts Poor Prognosis in Patients with Advanced Follicular Lymphoma Received Rituximab Plus BendamustineSemantic proximity Read ↗

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.Semantic proximity Read ↗

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.Semantic proximity Read ↗

Follicular lymphoma: are we ready for a risk-adapted approach?Semantic proximity Read ↗

Decreased expression of T-cell-associated immune markers predicts poor prognosis in patients with follicular lymphoma.Semantic proximity Read ↗

Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphoma.Semantic proximity Read ↗

Real-Life Disease Monitoring in Follicular Lymphoma Patients Using Liquid Biopsy Ultra-Deep Sequencing and PET/CTSemantic proximity Read ↗

Safety and Efficacy of Mosunetuzumab: Experience in the A.O. Card G. PanicoSemantic proximity Read ↗

High-grade Follicular Lymphomas Exhibit Clinicopathologic, Cytogenetic, and Molecular Diversity Extending Beyond Grades 3A and 3B.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.